ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 82 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $678,678 | -44.0% | 83,891 | +24.7% | 0.35% | +26.4% |
| Q3 2021 | $1,211,000 | -42.2% | 67,300 | -43.6% | 0.28% | -52.1% |
| Q2 2021 | $2,096,000 | -81.7% | 119,378 | -73.8% | 0.58% | -80.7% |
| Q1 2021 | $11,476,000 | +57.4% | 455,385 | -59.6% | 2.99% | +13.8% |
| Q4 2020 | $7,290,000 | +98.0% | 1,126,675 | -21.4% | 2.63% | +141.4% |
| Q3 2020 | $3,682,000 | +31.5% | 1,432,817 | -17.1% | 1.09% | +607.1% |
| Q2 2020 | $2,801,000 | +2.8% | 1,728,787 | -34.0% | 0.15% | -87.5% |
| Q1 2020 | $2,724,000 | -31.5% | 2,619,187 | +7.7% | 1.23% | -1.6% |
| Q4 2019 | $3,978,000 | +108.2% | 2,431,269 | +37.4% | 1.25% | +82.8% |
| Q3 2019 | $1,911,000 | -46.4% | 1,769,785 | +8.6% | 0.69% | -51.2% |
| Q2 2019 | $3,568,000 | +9.1% | 1,629,327 | +198.6% | 1.41% | +8.9% |
| Q1 2019 | $3,269,000 | – | 545,729 | – | 1.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |